stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
492.97 | 481.00 | 376.71 | 451.77 |
+8 more quarters Free account |
Revenue Growth |
39.15% | 47.67% | 42.23% | 51.60% | |
Cost of Revenue |
82.48 | 79.17 | 79.24 | 78.77 | |
Gross Profit |
410.50 | 401.83 | 297.47 | 373.00 | |
R&D Expenses |
27.78 | 27.66 | 25.56 | 316.78 | |
SG&A Expenses |
58.24 | 57.00 | 57.88 | 77.03 | |
Operating Income |
294.97 | 287.65 | 184.52 | (92.89) | |
Non-operating Interest Expenses |
6.05 | 5.59 | 5.51 | 4.91 | |
Non-operating Income/Expense |
(4.34) | (2.75) | (4.19) | (7.96) | |
| 290.63 | 284.90 | 180.33 | (100.85) | ||
Income Tax Provision |
43.58 | 54.99 | 30.28 | 40.74 | |
Income after Tax |
247.05 | 229.91 | 150.05 | (141.59) | |
Dividends (Preferred) |
— | 0.00 | — | — | |
Net Income Common |
247.05 | 229.91 | 150.05 | (141.59) | |
EPS (Basic) |
2.17 | 1.96 | 1.27 | (1.20) | |
EPS (Diluted) |
2.01 | 1.90 | 1.22 | (1.20) | |
Shares (Basic, Weighted) |
113.80 | 117.27 | 118.14 | 119.84 | |
Shares (Diluted, Weighted) |
122.61 | 121.22 | 122.88 | 123.90 | |
Gross Margin |
83.27% | 83.54% | 78.97% | 82.56% | |
EBIT Margin |
59.83% | 59.80% | 48.98% | (20.56%) | |
EBT margin |
58.95% | 59.23% | 47.87% | (22.32%) | |
Net Profit Margin |
50.11% | 47.80% | 39.83% | (31.34%) | |
EBITDA |
— | 323.27 | 220.47 | (64.36) | |
EBIT |
294.97 | 287.65 | 184.52 | (92.89) | |
Income from Continuous Operations |
247.05 | 229.91 | 150.05 | (141.59) | |
Consolidated Net Income/Loss |
247.05 | 229.91 | 150.05 | (141.59) | |
EPS (Basic, from Continuous Ops) |
2.17 | 1.96 | 1.27 | (1.17) | |
EPS (Diluted, from Cont. Ops) |
2.01 | 1.90 | 1.22 | (1.14) | |
EPS (Basic, Consolidated) |
2.17 | 1.96 | 1.27 | (1.17) | |
EPS (Diluted, Consolidated) |
2.01 | 1.90 | 1.22 | (1.14) | |
Shares (Diluted, Average) |
122.61 | 121.22 | 122.88 | 117.67 | |
EBITDA Margin |
0.00% | 67.21% | 58.52% | (14.25%) | |
Operating Cash Flow Margin |
52.39% | 50.08% | 47.80% | 48.48% |